WO2004089340A1 - Compositions pharmaceutiques, methode, et utilisation d'une formulation dans le traitement et la prevention d'infections associees a l'helicobacter pylori chez les mammiferes et les humains - Google Patents

Compositions pharmaceutiques, methode, et utilisation d'une formulation dans le traitement et la prevention d'infections associees a l'helicobacter pylori chez les mammiferes et les humains Download PDF

Info

Publication number
WO2004089340A1
WO2004089340A1 PCT/BR2003/000205 BR0300205W WO2004089340A1 WO 2004089340 A1 WO2004089340 A1 WO 2004089340A1 BR 0300205 W BR0300205 W BR 0300205W WO 2004089340 A1 WO2004089340 A1 WO 2004089340A1
Authority
WO
WIPO (PCT)
Prior art keywords
accordance
antibiotic
pharmaceutical composition
proton pump
tetracycline
Prior art date
Application number
PCT/BR2003/000205
Other languages
English (en)
Inventor
José PEDRAZZOLI JUNIOR
Original Assignee
Cmax Otimizacão De Resultados Sc Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cmax Otimizacão De Resultados Sc Ltda filed Critical Cmax Otimizacão De Resultados Sc Ltda
Priority to AU2003287797A priority Critical patent/AU2003287797A1/en
Publication of WO2004089340A1 publication Critical patent/WO2004089340A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/345—Nitrofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Definitions

  • the present invention relates to pharmaceutical compositions, which associate antibiotics with proton pump inhibitors and their applications in the treatment and prevention of infections caused by Helicobacter pylori . More precisely, the present invention relates to oral pharmaceutical compositions containing three active drugs against H. pylori infections, where at least an antibiotic belongs to nitrofuran class and is associated to at least a second antibiotic that can be of macrolide or tetracycline class and are associated to an proton pump inhibitor.
  • H. pylori infections where at least an antibiotic belongs to nitrofuran class and is associated to at least a second antibiotic that can be of macrolide or tetracycline class and are associated to an proton pump inhibitor.
  • H. pylori infection constitutes a relevant environmental acquired factor responsible for the pathogenesis of a wide spectrum of gastric and duodenal disorders. The infection is still acquired in childhood and the disease prevalence can reach 80% in adult individuals.
  • the World Health Organization considers this bacterium a carcinogenic agent of Group I for gastric cancer occurrence, including gastric carcinoma and lymphoma, and its eradication in positively diagnosed individuals is the best control against severe forms of the disease.
  • the H. pylori is sensitive to a series of antibiotics in vitro, in many treatments a transient suppression is observed but a complete eradication does not occur within a month after the treatment has finished. The development of appropriate eradication methods for chronic H.
  • pylori infections in vivo is not simple and currently it is only obtained by associating drugs having different action mechanisms.
  • the administration of a single antibiotic has showed not to be efficient to eradicate the infection and the association of two antibiotics not always showed to be effective.
  • the infection control and treatment are accomplished by combining antibiotics with drugs that reduces the acidity of the stomach, such as proton pump inhibitors. This process is known as triple therapy.
  • the main antibiotics used include bismuth salts
  • this patent includes sulfonamides, nimorazole, aminoglycosides (gentamycin, neomycin, canamycin, amicacin or streptomycin) ; macrolides as erythromycin, clindamycin or rifampicin; penicillins as penicillin G, penicillin V, ampicillin or mezlocillin; polypeptides as bacitracin or polymixin; tetracyclines, also including chlortetracycline, oxytetracycline, minocycline or doxycycline; or other antibiotics as carbapenems, cephalosporins, ciprofloxacin, norfloxacin, ofloxacin, pefloxacin; and, chloramphenicol .
  • the more used treatment consists in the association of a proton pump inhibitor with two or more antibiotics. As these drugs are available in different dosage forms, the treatment requests the administration of several pharmaceutical units a day.
  • a very used scheme relates to the association of the proton pump inhibitor with clarithromycin tablets (500 mg) and amoxicillin (1000 mg) b.i.d. or t.i.d. for the period from seven to fourteen days.
  • Several therapeutic schemes alternating antibiotics and proton pump inhibitors that should reach >90% infection inhibition levels are being evaluated.
  • nitroimidazoles and macrolides which have already been used in the initial treatment, it is not recommended and other antibiotics must be used.
  • a recent problem that has been particularly affecting the H. pylori infection treatment relates to the rapid development of strains resistant to clarithromycin treatment in the entire world where the drug is being used.
  • the proportion of clarithromycin-resistant H. pylori is increasing to a ratio of 2 to 5% a year.
  • a similar background relates to the emergence of metronidazole- resistant strains.
  • metronidazole-resistant strains In the case of Brazil, the emergence of treatment-resistant H. pylori strains has been observed with greater prevalence to metronidazole and amoxicillin antibiotics. In our studies the incidence of patients with resistant strains was 42% to metronidazole and 29% to amoxicillin.
  • the number of pharmaceutical units is high, being administered at least 3 to 6 units/day of dosage forms resulting in a series of discomforts to patient and increasing the treatment costs, as well as decreasing the treatment adhesion that is considered one of the main causes of the therapeutic failure.
  • the object of the present invention concerns to a new medicine and a new treatment and prevention method for recurrence of gastric infection caused by H. pylori .
  • the combined administration or drug association signifies that the association of an proton pump inhibitor with one or more interest antibiotics to combat the H. pylori infection can be made in the same formulation or in different formulations administered within a maximum of 24 hours (the treatment duration is from 7 to 14 days) .
  • the associations are preferentially available in a single device, e.g. single blister and can be made available in tablets or capsules containing alone or associated drugs, making easy the identification and the use for the patient.
  • the pharmaceutical composition of the present invention includes, added to the furazolidone, a second antibiotic that can be a macrolide antibiotic, preferentially clarithromycin or a tetracycline and a proton pump inhibitor.
  • a second antibiotic that can be a macrolide antibiotic, preferentially clarithromycin or a tetracycline and a proton pump inhibitor.
  • the proton pump inhibitor inclusion aids in the elimination of H. pylori and it can be useful for the treatment once patients frequently are dyspeptic at the beginning of the treatment.
  • a typical formulation that characterizes the present invention contains furazolidone, clarithromycin and omeprazole or furazolidone, tetracycline and omeprazole.
  • Lanzoprazole or pantoprazol can be an alternative proton pump inhibitor.
  • the patent US 6,132,768 describes an oral dosage form containing a proton pump inhibitor in combination, in the same formulation, with an antibiotic, where part of the proton pump inhibitor is slowly released.
  • This inhibitor can be presented in a pellet form and is associated to the antibiotic in capsules for oral use or both drugs can be contained in tablets. They can also be in different pharmaceutical units, but one of them, the one containing the inhibitor, of controlled release.
  • the patent US 6,136,344 describes an oral dosage form consisting of tablets, which associate at least an antibiotic with proton pump inhibitors in enteric-coated pellet form.
  • the antibiotics applied are amoxicillin, clarithromycin, metronidazole or a combination between them.
  • the patent US 6,319,904 describes a dosage form with adherence to the gastrointestinal tract associating an antibiotic and a proton pump inhibitor.
  • the antibiotics mentioned in it include benzylpenicillin, piperacillin, mecillinam, cefixime, cefaclor and erythromycin.
  • compositions comprising at least two antibiotics associated to a proton pump inhibitor.
  • the association of antibiotics is necessary in order to reach at least 90% of bacterium elimination that allows reducing the treatment duration and thus avoiding the emergence of resistant strains.
  • omeprazole increases the clarithromycin concentration in gastric juice of patients infected with JJ. pylori .
  • the novelty of the present invention relates to the association of two antibiotics, being furazolidone the first and clarithromycin or tetracycline the second, with a proton pump inhibitor in a single oral formulation in order to explore the advantages of this association against Helicobacter infection in mammals and humans.
  • the present invention makes available, in an acceptable pharmaceutical vehicle, an oral pharmaceutical composition aiming treatment of gastric disorders caused by JJ. pylori , including furazolidone as a first antibiotic and a second antibiotic of the tetracycline or macrolide group and a proton pump inhibitor.
  • the present invention makes available, in an acceptable pharmaceutical vehicle, a therapeutic method for the treatment and prevention of JJ. pylori infection in treatment-resistant and -sensitive patients using the conventional drugs and therapeutic methods, involving the administration of safety and effective therapeutic doses of a dosage form that contains, in the same formulation, furazolidone as a first antibiotic and a second antibiotic of the tetracycline or macrolide group and a proton pump inhibitor.
  • compositions of the present invention used in the methods proposed by the present invention, should be prepared using state-of-the-art knowledge techniques, which involve the unitary operations of homogenization, mixture, humectation, granulation, drying, compression, micronization, coating, dispersion, among other available techniques, should involve in the composition the excipients necessary for developing oral dosage forms that are known by the state-of-the-art.
  • the pharmaceutical composition should be presented in tablets, pellets, capsules, pastilles, suspensions, and powders in sachets or lyophilized powder form for suspension. Techniques of slow or sustained-release should be applied in a granule form or coated particles, multilayer-tablets, or microgranules.
  • the concentrations of antibiotics and proton pump inhibitor in pharmaceutical compositions and therapeutic methods proposed in the present invention are in accordance with the available data that assures the safety and effectiveness in the eradication of JJ. pylori infection.
  • the typical dose of furazolidone is 50 to 1000 mg/day, being typically used 100 to 200 mg per formulation and can be administered b.i.d or t.i.d.
  • the typical dose is between 50 mg/day and 4000 mg/day, the most typical dose used is 2000 mg/day.
  • For clarithromycin the typical dose is between 50 mg/day and 4000 mg/day, the most typical dose used is 1000 mg/day.
  • proton pump inhibitors the typical dose ranges between 20 and 500 mg, more typically around 20 to 80 mg/day.
  • compositions above mentioned can be administered once a day or more, but preferably one to three times a day until the infection eradication that can range from seven to fourteen days and can be extended to 28 days at the doctor's discretion.
  • Example 1 The present invention can be better illustrated by the following examples: Example 1
  • All formulations provided in the present invention were prepared from wet granulation that results in a granulate that can be used in a second stage of compression or capsule filling. Due to the powder volume for each formulation, each unit was designed for obtaining tablets of -750 to 1000 mg (total individual weight), or capsules 0 and 00.
  • the selected formulations contain in its composition: furazolidone (100 to 200 mg) , clarithromycin (500 mg) or tetracycline (500 to 600 mg) , and omeprazole (20 to 40 mg) .
  • the humectation was obtained using water or aqueous solutions containing gelatin, sucrose or hydroalcoholic solutions, or organic solutions containing polymer.
  • derivatives of Eudragit S100, L100, RTML and NE30D
  • derivatives of poly-esters as poly- ⁇ - caprolactone or derivatives of poly-lactic and glycolic acid that were used in the organic solution form, or aqueous dispersion of nanoparticles previously prepared.
  • Lactose, cellulose and derivatives were used as diluent and starch, PVP or gelatin were used as agglutinant agents.
  • Triethyl citrate and butyl diphthalate were used as plasticizer.
  • Magnesium Stearate were used to optimize the granulate fluidity. To obtain the granulates and tablets, spray dryer and coating techniques by atomization were used. Table I. Mass Composition and percentage of antibiotic granulated/tablet formulation and omeprazole.
  • TOTAL 1000 100 The methodology used in the preparation of clarithromycin-containing granulate was the wet granulation.
  • the description of the technique employed to prepare this formulation is the following: - To weigh and sieve all components by using a 14-mesh sieve; soon afterwards, the powders A, B, C, D, E, and F are mixed. The mixture was humidified by adding slowly and gradually 50 to 70 mL of deionized water and then homogenized until a homogeneous wet mass is formed. This wet mixture was passed through a 14-mesh sieve and immediately after dried in a stove at 37°C over twelve hours, until obtaining a granulate with moisture residue ⁇ 2%.
  • a gelatin solution can be used for the humectation.
  • the granulate was calibrated in a 14-mesh sieve. This granulate was coated by atomization or spray dryer with solutions of Eudragit S100, LlOO, RTML, or NE30D or polymeric nanoparticles at concentrations from 5 to 15%. The coated granulate has been used for filling the capsules or, after addition of magnesium stearate, the tablets were obtained from appropriate compression machine.
  • This granulate was coated by atomization or spray dryer with solutions of Eudragit S100, LlOO, RTML, or NE30D or polymeric nanoparticles at concentrations from 5 to 15%.
  • Magnesium stearate was added to granulate that was used for filling the capsules or the tablets were obtained from appropriate compression machine.
  • the tablets can be obtained before the polymeric coating and be coated by atomization with these solutions.
  • Magnesium stearate was added to the granulate and was used for filling the capsules following the addition of component A or, after addition of magnesium stearate, the tablets were obtained from appropriate compression machine. Optionally, the tablets can be obtained before the polymeric coating and be coated by atomization with these solutions.
  • Example 3
  • the granulate was dried in a stove at 37 °C for 12 H, enough time to obtain a residue with moisture lower than 2%.
  • the granulate was calibrated in a 24-mesh sieve and then the component H was added.
  • the granulate was compressed. Following the compression, the tablets were coated with Eudragit S100 or Eudragit LlOO solution in isopropyl alcohol, containing a binding agent at 10% w/w polymer concentration.
  • TOTAL 110 100 Dry granulation was the methodology used in the preparation of the granulate of Formulation 1. The technique used for preparing this formulation is described below: - To weigh all components using a semi-analytical balance and sieve the powders previously weighed by using a 14-mesh sieve. With the aid of a pistil, moisten the component F (cyclodextrin) with ethanol in a mortar and add the tetracycline. To homogenize the mixture for approximately 30 minutes and evaporate the solvent under vacuum for approximately 12 hours. After drying, with the aid of a pistil, grind the mixture and sieve by using a 24- mesh sieve. After that, the other drugs B and C were individually granulated in the presence of Eudragit S100.
  • F cyclodextrin
  • an Eudragit solution in acetone or isopropyl alcohol containing a plasticizer (dibutyl phthalate or triethyl citrate at 10% w/w polymer concentration) was prepared and sieved through a 24-mesh sieve.
  • a plasticizer dibutyl phthalate or triethyl citrate at 10% w/w polymer concentration
  • the obtained granulates were mixed with components D and E, and then this mixture was homogenized.
  • the obtained granulate was calibrated in 24-mesh sieve and the component H was added.
  • the granulate was compressed. Following the compression, the tablets were coated with Eudragit S100 or Eudragit LlOO solution in isopropyl alcohol or acetone, containing a binding agent at 10% w/w polymer concentration.
  • Example 5 Drug-Release Kinetics
  • the tablets obtained from the examples above were subjected to a study of release kinetics. After the tablet incubation with approximately 900 to lOOOmL hydrochloric acid 0.1 M, in the first two hours samples were collected and subjected to analysis by HPLC. Two hours later, the pH was adjusted between 6.8 and 7.5 with phosphate buffer and samples were collected over 4 to 6 subsequent hours. In the first two hours, no amount of drug was detected in the collected samples and the tablets remained intact in acid medium. After the medium alkalinization, a degradation of the coating layer happens and the total drugs are released within the studied period.
  • Example 6 Treatment of patients with JJ. pylori infection
  • the oral solid dosage forms, object of the present invention can still contain other pharmaceutical degree excipients, such as binders, disintegrating agents, diluents, coating agents, lubricants and sustained-release agents.
  • binders such as gelatin, starch, sodium alginate, carboxymethylcellulose, hydroxymethylpropylcellulose, ethylpropylmethylcellulose, polyethylene glycol, and lactose.
  • the disintegrating agents can include starch, methylcellulose, polyvinylpyrrolidone, xanthan gum, bentonite, and alginates.
  • the diluents that best allow obtaining the present invention include lactose, sorbitol, mannitol, dextrose, cellulose and derivatives, calcium carbonate.
  • the coating agents we can include acrylic acid polymers and co-polymers, and methacrylates and their esters, waxes and derivatives of polymers and co-polymers prepared from lactic and glycolic acid polyesters and from caprolactone.
  • the most desirable lubricants include magnesium stearate, calcium stearate, stearic acid, sodium oleate, talc.
  • the binding agents the most desirable are triethyl citrate, butyl phthalate and polyethylene glycol.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques, associant des antibiotiques à des inhibiteurs de la pompe à protons, et leurs applications dans le traitement et la prévention d'infections causées par Helicobacter pylori. La présente invention concerne plus précisément des compositions pharmaceutiques orales contenant trois médicaments actifs contre les infections causées par H. pylori, avec au moins un antibiotique appartenant à la classe des nitrofurannes et associé à un second antibiotique au moins, pouvant être de la classe des macrolides ou des tétracyclines, lesdits antibiotiques étant associés à un inhibiteur de la pompe à protons.
PCT/BR2003/000205 2003-04-09 2003-12-29 Compositions pharmaceutiques, methode, et utilisation d'une formulation dans le traitement et la prevention d'infections associees a l'helicobacter pylori chez les mammiferes et les humains WO2004089340A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003287797A AU2003287797A1 (en) 2003-04-09 2003-12-29 Pharmaceutical compositions, method, and use of formulation for the treatment and prevention of infections associated with helicobacter pylori in mammals and humans

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BRPI0300882-7 2003-04-09
BR0300882-7A BR0300882A (pt) 2003-04-09 2003-04-09 Composições farmacêuticas, método e uso de formulação para tratamento e prevenção de infecções associadas com helicobacter pylori em mamìferos e no ser humano

Publications (1)

Publication Number Publication Date
WO2004089340A1 true WO2004089340A1 (fr) 2004-10-21

Family

ID=33136628

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2003/000205 WO2004089340A1 (fr) 2003-04-09 2003-12-29 Compositions pharmaceutiques, methode, et utilisation d'une formulation dans le traitement et la prevention d'infections associees a l'helicobacter pylori chez les mammiferes et les humains

Country Status (3)

Country Link
AU (1) AU2003287797A1 (fr)
BR (1) BR0300882A (fr)
WO (1) WO2004089340A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1905426A2 (fr) * 2006-06-05 2008-04-02 Laboratorios Bagó S.A. Composition pharmaceutique anti-acide sous forme de poudre, préparation pharmaceutique la contenant et son processus de fabrication
WO2008114143A1 (fr) * 2007-03-22 2008-09-25 Aurobindo Pharma Limited Formulations à libération prolongée d'un antibiotique macrolide
WO2011079349A1 (fr) * 2009-12-31 2011-07-07 Okada Medical Services Pty Ltd Okadaella gastrococcus et cancer
EP3034077A1 (fr) * 2014-12-15 2016-06-22 Ems S.A. Kit pour co-administration d' esomeprazole, amoxicillin et clarithromycin

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997002021A1 (fr) * 1995-07-05 1997-01-23 Byk Gulden Lomberg Chemische Fabrik Gmbh Composition pharmaceutique administrable par voie orale a liberation differee d'un ingredient actif d'inhibiteurs reversibles de la pompe a protons
WO1997002020A1 (fr) * 1995-07-05 1997-01-23 Byk Gulden Lomberg Chemische Fabrik Gmbh Composition pharmaceutique administrable par voie orale contenant des agents actifs antimicrobiens et du pantoprazole a liberation differee

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997002021A1 (fr) * 1995-07-05 1997-01-23 Byk Gulden Lomberg Chemische Fabrik Gmbh Composition pharmaceutique administrable par voie orale a liberation differee d'un ingredient actif d'inhibiteurs reversibles de la pompe a protons
WO1997002020A1 (fr) * 1995-07-05 1997-01-23 Byk Gulden Lomberg Chemische Fabrik Gmbh Composition pharmaceutique administrable par voie orale contenant des agents actifs antimicrobiens et du pantoprazole a liberation differee

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1905426A2 (fr) * 2006-06-05 2008-04-02 Laboratorios Bagó S.A. Composition pharmaceutique anti-acide sous forme de poudre, préparation pharmaceutique la contenant et son processus de fabrication
EP1905426A3 (fr) * 2006-06-05 2008-05-21 Laboratorios Bagó S.A. Composition pharmaceutique anti-acide sous forme de poudre, préparation pharmaceutique la contenant et son processus de fabrication
US7968118B2 (en) 2006-06-05 2011-06-28 Laboratorios Bago S.A. Anti-acid pharmaceutical composition in powder form and process for making it
US8093271B2 (en) 2006-06-05 2012-01-10 Laboratorios Bago S.A. Anti-acid pharmaceutical composition in powder form and process for making it
WO2008114143A1 (fr) * 2007-03-22 2008-09-25 Aurobindo Pharma Limited Formulations à libération prolongée d'un antibiotique macrolide
WO2011079349A1 (fr) * 2009-12-31 2011-07-07 Okada Medical Services Pty Ltd Okadaella gastrococcus et cancer
US20130172298A1 (en) * 2009-12-31 2013-07-04 Takayuki Okada Okadaella Gastrococcus and Cancer
US9511080B2 (en) 2009-12-31 2016-12-06 Okada Medical Services Pty Ltd Okadaella gastrococcus and cancer
EP3034077A1 (fr) * 2014-12-15 2016-06-22 Ems S.A. Kit pour co-administration d' esomeprazole, amoxicillin et clarithromycin

Also Published As

Publication number Publication date
BR0300882A (pt) 2005-05-10
AU2003287797A1 (en) 2004-11-01

Similar Documents

Publication Publication Date Title
RU2681315C2 (ru) Лекарственные формы для пероральной доставки адсорбентов в кишечник
US6132768A (en) Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
US11135172B2 (en) Rifabutin-based compositions and methods for treating Helicobacter pylori infection
US20060165797A1 (en) Dosage form for treating gastrointestinal disorders
MXPA96004354A (en) New form of pharmaceutical dosage or
BG105203A (bg) Фармацевтична таблетка с разграждащо се в черватапокритие и метод за получаване
JP2009530367A (ja) 調節放出性抗生組成物およびその製造方法
EP2012756A2 (fr) Compositions à unités multiples
CN107308130B (zh) 包衣药物球状体及消除或减少病症如呕吐和腹泻的用途
KR20090029830A (ko) 소장 내에서 활성성분의 방출이 제어되는 경구투여용 약제학적 조제물 및 그의 제조방법
KR100581967B1 (ko) 소화성 궤양 치료를 위한 프로톤펌프 저해제와클래리스로마이신을 함유하는 이중 펠렛 제제 및 그의제조방법
WO2004089340A1 (fr) Compositions pharmaceutiques, methode, et utilisation d'une formulation dans le traitement et la prevention d'infections associees a l'helicobacter pylori chez les mammiferes et les humains
CN114569575A (zh) 肠溶微丸、其制备方法和包含它的制剂
EP1841409A2 (fr) Forme dosifiee contre les troubles gastro-intestinaux
US20240033224A1 (en) Enteric-coated pellet, method for preparing same and formulation comprising same
WO2021186354A1 (fr) Formulations pharmaceutiques à libération contrôlée pour le traitement d'infections intestinales
KR20090131706A (ko) 위장관 궤양의 치료를 위한 매스틱 함유 복합제제
NZ625506A (en) Compositions for treatment of heart failure in dogs.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP